Cargando…

A comprehensive profile of TCF1(+) progenitor and TCF1(−) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy

The heterogeneity of exhausted T cells (Tex) is a critical determinant of immune checkpoint blockade therapy efficacy. However, few studies have explored exhausted T cell subpopulations in human cancers. In the present study, we examined samples from two cohorts of 175 patients with head and neck sq...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dikan, Fang, Juan, Wen, Shuqiong, Li, Qunxing, Wang, Jinming, Yang, Lisa, Dai, Wenxiao, Lu, Huanzi, Guo, Junyi, Shan, Zhongyan, Xie, Wenqiang, Liu, Xiangqi, Wen, Liling, Shen, Jie, Wang, Anxun, Chen, Qianming, Wang, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841504/
https://www.ncbi.nlm.nih.gov/pubmed/35153298
http://dx.doi.org/10.1038/s41368-022-00160-w
_version_ 1784650852295770112
author Wang, Dikan
Fang, Juan
Wen, Shuqiong
Li, Qunxing
Wang, Jinming
Yang, Lisa
Dai, Wenxiao
Lu, Huanzi
Guo, Junyi
Shan, Zhongyan
Xie, Wenqiang
Liu, Xiangqi
Wen, Liling
Shen, Jie
Wang, Anxun
Chen, Qianming
Wang, Zhi
author_facet Wang, Dikan
Fang, Juan
Wen, Shuqiong
Li, Qunxing
Wang, Jinming
Yang, Lisa
Dai, Wenxiao
Lu, Huanzi
Guo, Junyi
Shan, Zhongyan
Xie, Wenqiang
Liu, Xiangqi
Wen, Liling
Shen, Jie
Wang, Anxun
Chen, Qianming
Wang, Zhi
author_sort Wang, Dikan
collection PubMed
description The heterogeneity of exhausted T cells (Tex) is a critical determinant of immune checkpoint blockade therapy efficacy. However, few studies have explored exhausted T cell subpopulations in human cancers. In the present study, we examined samples from two cohorts of 175 patients with head and neck squamous cell cancer (HNSCC) by multiplex immunohistochemistry (mIHC) to investigate two subsets of Tex, CD8(+)PD1(+)TCF1(+) progenitor exhausted T cells (TCF1(+)Tex(prog)) and CD8(+)PD1(+)TCF1(−) terminally exhausted T cells (TCF1(−)Tex(term)). Moreover, fresh tumor samples from 34 patients with HNSCC were examined by flow cytometry and immunohistochemistry to further investigate their properties and cytotoxic capabilities and their correlation with regulatory T cells (Tregs) in the tumor immune microenvironment (TIME). mIHC and flow cytometry analysis showed that TCF1(−)Tex(term) represented a greater proportion of CD8(+)PD1(+)Tex than TCF1(+)Tex(prog) in most patients. TCF1(+)Tex(prog) produced abundant TNFα, while TCF1(−)Tex(term) expressed higher levels of CD103, TIM-3, CTLA-4, and TIGIT. TCF1(−)Tex(term) exhibited a polyfunctional TNFα(+)GZMB(+)IFNγ(+) phenotype; and were associated with better overall survival and recurrence-free survival. The results also indicated that larger proportions of TCF1(−)Tex(term) were accompanied by an increase in the proportion of Tregs. Therefore, it was concluded that TCF1(−)Tex(term) was the major CD8(+)PD1(+)Tex subset in the HNSCC TIME and that these cells favor patient survival. A high proportion of TCF1(−)Tex(term) was associated with greater Treg abundance.
format Online
Article
Text
id pubmed-8841504
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88415042022-03-02 A comprehensive profile of TCF1(+) progenitor and TCF1(−) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy Wang, Dikan Fang, Juan Wen, Shuqiong Li, Qunxing Wang, Jinming Yang, Lisa Dai, Wenxiao Lu, Huanzi Guo, Junyi Shan, Zhongyan Xie, Wenqiang Liu, Xiangqi Wen, Liling Shen, Jie Wang, Anxun Chen, Qianming Wang, Zhi Int J Oral Sci Article The heterogeneity of exhausted T cells (Tex) is a critical determinant of immune checkpoint blockade therapy efficacy. However, few studies have explored exhausted T cell subpopulations in human cancers. In the present study, we examined samples from two cohorts of 175 patients with head and neck squamous cell cancer (HNSCC) by multiplex immunohistochemistry (mIHC) to investigate two subsets of Tex, CD8(+)PD1(+)TCF1(+) progenitor exhausted T cells (TCF1(+)Tex(prog)) and CD8(+)PD1(+)TCF1(−) terminally exhausted T cells (TCF1(−)Tex(term)). Moreover, fresh tumor samples from 34 patients with HNSCC were examined by flow cytometry and immunohistochemistry to further investigate their properties and cytotoxic capabilities and their correlation with regulatory T cells (Tregs) in the tumor immune microenvironment (TIME). mIHC and flow cytometry analysis showed that TCF1(−)Tex(term) represented a greater proportion of CD8(+)PD1(+)Tex than TCF1(+)Tex(prog) in most patients. TCF1(+)Tex(prog) produced abundant TNFα, while TCF1(−)Tex(term) expressed higher levels of CD103, TIM-3, CTLA-4, and TIGIT. TCF1(−)Tex(term) exhibited a polyfunctional TNFα(+)GZMB(+)IFNγ(+) phenotype; and were associated with better overall survival and recurrence-free survival. The results also indicated that larger proportions of TCF1(−)Tex(term) were accompanied by an increase in the proportion of Tregs. Therefore, it was concluded that TCF1(−)Tex(term) was the major CD8(+)PD1(+)Tex subset in the HNSCC TIME and that these cells favor patient survival. A high proportion of TCF1(−)Tex(term) was associated with greater Treg abundance. Nature Publishing Group UK 2022-02-14 /pmc/articles/PMC8841504/ /pubmed/35153298 http://dx.doi.org/10.1038/s41368-022-00160-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Wang, Dikan
Fang, Juan
Wen, Shuqiong
Li, Qunxing
Wang, Jinming
Yang, Lisa
Dai, Wenxiao
Lu, Huanzi
Guo, Junyi
Shan, Zhongyan
Xie, Wenqiang
Liu, Xiangqi
Wen, Liling
Shen, Jie
Wang, Anxun
Chen, Qianming
Wang, Zhi
A comprehensive profile of TCF1(+) progenitor and TCF1(−) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy
title A comprehensive profile of TCF1(+) progenitor and TCF1(−) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy
title_full A comprehensive profile of TCF1(+) progenitor and TCF1(−) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy
title_fullStr A comprehensive profile of TCF1(+) progenitor and TCF1(−) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy
title_full_unstemmed A comprehensive profile of TCF1(+) progenitor and TCF1(−) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy
title_short A comprehensive profile of TCF1(+) progenitor and TCF1(−) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy
title_sort comprehensive profile of tcf1(+) progenitor and tcf1(−) terminally exhausted pd-1(+)cd8(+) t cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841504/
https://www.ncbi.nlm.nih.gov/pubmed/35153298
http://dx.doi.org/10.1038/s41368-022-00160-w
work_keys_str_mv AT wangdikan acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT fangjuan acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wenshuqiong acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT liqunxing acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wangjinming acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT yanglisa acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT daiwenxiao acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT luhuanzi acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT guojunyi acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT shanzhongyan acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT xiewenqiang acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT liuxiangqi acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wenliling acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT shenjie acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wanganxun acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT chenqianming acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wangzhi acomprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wangdikan comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT fangjuan comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wenshuqiong comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT liqunxing comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wangjinming comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT yanglisa comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT daiwenxiao comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT luhuanzi comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT guojunyi comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT shanzhongyan comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT xiewenqiang comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT liuxiangqi comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wenliling comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT shenjie comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wanganxun comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT chenqianming comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy
AT wangzhi comprehensiveprofileoftcf1progenitorandtcf1terminallyexhaustedpd1cd8tcellsinheadandnecksquamouscellcarcinomaimplicationsforprognosisandimmunotherapy